Home › Multiple Myeloma › Oregon › Portland
Multiple Myeloma clinical trials in Portland, OR
13 studies for Multiple Myeloma are looking for participants at sites in and around Portland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RecruitingPhase 3
- Research Site, Portland
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
- Oregon Health And Science University, Portland
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
RecruitingObservational study
- OHSU Knight Cancer Institute, Portland
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecruitingPhase 2
- Providence Health & Services, Portland
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 2
- Oregon Health and Science University, Portland
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RecruitingPhase 1/2
- Oregon Health and Science University /ID# 272282, Portland
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
RecruitingPhase 1
- Providence Portland Medical Center, Portland
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RecruitingPhase 3
- Research Site, Portland
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RecruitingPhase 2
- Oregon Health & Science University, Portland
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
RecruitingPhase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi away
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1/2
- Oregon Health and Science University (OHSU) Marquam Hill Campus, Portland
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
RecruitingObservational study
- Local Institution - 0016, Portland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RecruitingObservational studyHealthy volunteers welcome
- Oregon Health Sciences University, Portland
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA41 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO27 studies
- Rochester, MN24 studies
- St. Louis, MO24 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- Chicago, IL22 studies
Other studies in Portland
- Non-Small Cell Lung Cancer46 studies
- Cancer (all types)34 studies
- Prostate Cancer33 studies
- Breast Cancer33 studies
- Metastatic Cancer29 studies
- Colorectal Cancer28 studies
- Ovarian Cancer27 studies
- Lung Cancer26 studies
- Acute Myeloid Leukemia25 studies
- Endometrial Cancer24 studies
- Head and Neck Squamous Cell Carcinoma19 studies
- Pancreatic Cancer19 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.